GRFS vs. LVTX, MYNZ, NLSP, PHVS, PROC, QLI, ATNFW, SXTPW, ACONW, and AIMDW
Should you be buying Grifols stock or one of its competitors? The main competitors of Grifols include LAVA Therapeutics (LVTX), Mainz Biomed (MYNZ), NLS Pharmaceutics (NLSP), Pharvaris (PHVS), Procaps Group (PROC), Qilian International Holding Group (QLI), 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Aclarion (ACONW), and Ainos (AIMDW). These companies are all part of the "medical" sector.
Grifols (NASDAQ:GRFS) and LAVA Therapeutics (NASDAQ:LVTX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability, valuation and community ranking.
Grifols has higher revenue and earnings than LAVA Therapeutics.
Grifols has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Comparatively, LAVA Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.
Grifols has a net margin of 0.90% compared to LAVA Therapeutics' net margin of -620.09%. Grifols' return on equity of 1.73% beat LAVA Therapeutics' return on equity.
Grifols received 326 more outperform votes than LAVA Therapeutics when rated by MarketBeat users. However, 75.86% of users gave LAVA Therapeutics an outperform vote while only 55.95% of users gave Grifols an outperform vote.
In the previous week, Grifols had 5 more articles in the media than LAVA Therapeutics. MarketBeat recorded 5 mentions for Grifols and 0 mentions for LAVA Therapeutics. Grifols' average media sentiment score of 0.04 beat LAVA Therapeutics' score of 0.00 indicating that Grifols is being referred to more favorably in the media.
Grifols presently has a consensus price target of $10.50, suggesting a potential upside of 36.36%. LAVA Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 127.27%. Given LAVA Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe LAVA Therapeutics is more favorable than Grifols.
Summary
Grifols beats LAVA Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Grifols News Delivered to You Automatically
Sign up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GRFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
